SpringWorks Therapeutics Inc (NASDAQ: SWTX) kicked off on Monday, down -0.94% from the previous trading day, before settling in for the closing price of $36.16. Over the past 52 weeks, SWTX has traded in a range of $28.21-$53.92.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -25.00% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 39.49%. With a float of $65.76 million, this company’s outstanding shares have now reached $74.34 million.
In an organization with 305 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 93.59%, operating margin of -217.92%, and the pretax margin is -203.09%.
SpringWorks Therapeutics Inc (SWTX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of SpringWorks Therapeutics Inc is 11.59%, while institutional ownership is 101.74%. The most recent insider transaction that took place on Dec 03 ’24, was worth 839,336. In this transaction Chief Operating Officer of this company sold 20,000 shares at a rate of $41.97, taking the stock ownership to the 209,600 shares. Before that another transaction happened on Dec 02 ’24, when Company’s Chief Executive Officer sold 49,000 for $41.37, making the entire transaction worth $2,027,357. This insider now owns 1,014,368 shares in total.
SpringWorks Therapeutics Inc (SWTX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.66 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 39.49% per share during the next fiscal year.
SpringWorks Therapeutics Inc (NASDAQ: SWTX) Trading Performance Indicators
Take a look at SpringWorks Therapeutics Inc’s (SWTX) current performance indicators. Last quarter, stock had a quick ratio of 6.02. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 19.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.73, a number that is poised to hit -0.67 in the next quarter and is forecasted to reach -2.12 in one year’s time.
Technical Analysis of SpringWorks Therapeutics Inc (SWTX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.52 million. That was inferior than the volume of 1.93 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 49.45%. Additionally, its Average True Range was 2.84.
During the past 100 days, SpringWorks Therapeutics Inc’s (SWTX) raw stochastic average was set at 43.64%, which indicates a significant increase from 28.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 101.25% in the past 14 days, which was higher than the 56.08% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $37.86, while its 200-day Moving Average is $37.76. However, in the short run, SpringWorks Therapeutics Inc’s stock first resistance to watch stands at $37.88. Second resistance stands at $39.94. The third major resistance level sits at $41.20. If the price goes on to break the first support level at $34.56, it is likely to go to the next support level at $33.30. Assuming the price breaks the second support level, the third support level stands at $31.24.
SpringWorks Therapeutics Inc (NASDAQ: SWTX) Key Stats
The company with the Market Capitalisation of 2.66 billion has total of 74,386K Shares Outstanding. Its annual sales at the moment are 5,450 K in contrast with the sum of -325,100 K annual income. Company’s last quarter sales were recorded 49,300 K and last quarter income was -53,530 K.
